Zydus Lifesciences Limited
All news and filings related to Zydus Lifesciences Limited.
View all news & filings- Medium impact
USFDA Inspection Concludes at Zydus' Ahmedabad Plant; One Observation Issued
The USFDA conducted a cGMP inspection at Zydus' Ahmedabad plant from September 21-28, 2026. The inspection concluded with one observation, with no data integrity issues noted. Zydus will work with the USFDA to address the observation.
Read the summary - Low impact
Zydus Lifesciences Declares Trading Window Closure from Oct 1, 2026
Zydus Lifesciences Limited announced a trading window closure for Directors and Designated Persons from October 1, 2026. The window will reopen 48 hours after the declaration of unaudited financial results for the quarter/half-year ending September 30, 2026. The Board meeting date for results approval will be announced later.
Read the summary - Medium impact
Zydus Lifesciences USA Office USFDA Inspection Concludes with Nil Observations
The USFDA inspected Zydus Lifesciences' USA office for pharmacovigilance and post-marketing surveillance systems from September 22-25, 2026. The inspection concluded with zero observations, indicating strong compliance.
Read the summary - Low impact
Zydus Lifesciences Limited Announces Loss of Share Certificate
Zydus Lifesciences Limited published a notice about a lost share certificate for Mr. MUld Narayana. The certificate covers 1500 shares. A duplicate will be issued if no objections are raised within seven days of the September 24, 2026 publication.
Read the summary - Low impact
Zydus Lifesciences Announces Special Window for Security Transfers and Dematerialisation
Zydus Lifesciences has opened a special window from February 5, 2026, to February 4, 2027, for transferring and dematerialising physical securities purchased before April 1, 2019. Transferred securities will be dematerialised and locked in for one year. Investors must submit documents to MUFG India Private Limited by February 4, 2027.
Read the summary - Medium impact
Zydus Lifesciences: CRISIL Reaffirms 'CRISIL AAA/Stable' and 'CRISIL A1+' Ratings
CRISIL Ratings has reaffirmed Zydus Lifesciences' credit ratings. The long-term rating for bank facilities (₹4,724 crore) is CRISIL AAA/Stable, and the short-term rating is CRISIL A1+. Commercial Papers (₹200 crore) and NCDs (₹50 crore and ₹75 crore) also retain their respective ratings.
Read the summary - Low impact
Zydus Lifesciences to Participate in J.P. Morgan India Conference on Sep 21, 2026
Zydus Lifesciences will participate in the J.P. Morgan India Conference on September 21, 2026. This event is an opportunity for the company to connect with analysts and institutional investors.
Read the summary - Low impact
Zydus Lifesciences Issues Notice for Lost Share Certificates
Zydus Lifesciences Limited announced the loss of share certificates belonging to shareholders Vivian John D Souza and Noreen D Souza. The company will issue duplicate certificates if no objections are raised within 7 days of the September 9, 2026, publication date.
Read the summary - Low impact
Zydus Lifesciences Subsidiary ZPUI to Pay USD 5.9 Million to Settle US Litigation
Zydus Lifesciences' US subsidiary, ZPUI, will pay USD 5.9 million (approx. ₹49.1 crore) to settle ongoing litigation in the US. The settlement resolves claims related to generic pharmaceuticals pricing antitrust litigation.
Read the summary - Medium impact
Zydus Lifesciences Transcripts 31st AGM Held on August 11, 2026
Zydus Lifesciences Limited held its 31st AGM on August 11, 2026. Consolidated revenues for FY2025-26 were ₹271.5 billion (₹27,150 crore), a 17% increase. The company announced a share buyback of up to ₹1,100 crore at ₹1,260 per share. A dividend of ₹1 per share was declared. The AGM also covered financial statements, director appointments, and business updates.
Read the summary - Medium impact
Zydus Lifesciences Announces Positive Topline Results from EVIDENCES-X Phase II(b) MASH Trial
Zydus Lifesciences announced positive topline results from its EVIDENCES-X™ Phase II(b) MASH clinical trial. The trial met its primary endpoint, showing resolution of steatohepatitis with no worsening of fibrosis. This reinforces the therapeutic potential of Saroglitazar Mg for MASH patients.
Read the summary - Low impact
Zydus Lifesciences Incorporates Wholly Owned Subsidiary in GIFT City
Zydus Lifesciences Limited has incorporated a wholly owned subsidiary, Zydus Global Treasury Centre IFSC Limited, in GIFT City. The subsidiary has an authorized and paid-up share capital of ₹5 Crores and will focus on global and regional corporate treasury activities.
Read the summary - Low impact
Zydus Lifesciences Gets Strong ESG Score of 66 from CRISIL Ratings
Zydus Lifesciences Limited's ESG score has been upgraded to 66 by CRISIL Ratings, indicating a 'strong' performance. The previous score was 61. The assessment is based on data from the financial year 2025-2026.
Read the summary - Low impact
Zydus Lifesciences: Promoter Group Member Receives 32,577 Equity Shares via Transmission
Zydus Lifesciences Limited announced the transmission of 32,577 equity shares to Mr. Prashant Babubhai Patel, a promoter group member, from the late Jasodaben Babubhai Patel. The disclosure was made on August 21, 2026, as per SEBI (PIT) Regulations.
Read the summary - Medium impact
Zydus Lifesciences Presents Investor Presentation for Investor Conference
Zydus Lifesciences Limited has released an investor presentation for an upcoming conference. The company reported FY26 revenue over US$3 billion and a market cap exceeding US$11.7 billion. Key segments include India Formulations, North America, Consumer Wellness, and MedTech. The presentation details R&D pipeline, including Saroglitazar for PBC and Usnoflast for ALS.
Read the summary - Low impact
Zydus Lifesciences Receives ESG Rating of 60 from ESGRAIL
Zydus Lifesciences Limited received an overall ESG rating of 60 from ESGRAIL. The rating was independently prepared by ESGRAIL based on publicly available information.
Read the summary - Medium impact
Zydus Lifesciences Receives USFDA Final Approval for Ascorbic Acid Injection with CGT Exclusivity
Zydus Lifesciences received final USFDA approval for Ascorbic Acid Injection USP, eligible for 180-day CGT exclusivity. The product is manufactured in Gujarat and will be marketed in the US. The brand product had annual sales of approximately USD 11.6 million (approx. ₹96.5 crore).
Read the summary - High impact
Zydus Lifesciences Q1 FY27 Earnings Call Transcript Released; Consolidated Revenue Up 22%
Zydus Lifesciences reported Q1 FY27 consolidated revenues of ₹80.2 billion (up 22% YoY), with EBITDA at ₹19.3 billion and net profit at ₹9.4 billion. The company reaffirmed its guidance for strong double-digit growth for FY27. Key developments include the US launch of its first biosimilar, NufymcoTM, and the acquisition of Assertio Holdings. The branded portfolio now constitutes over 55% of revenue, with a medium-term target of over two-thirds.
Read the summary - Low impact
Zydus Lifesciences to Conduct Non-Deal Roadshow in Singapore and Hong Kong from Aug 24-26
Zydus Lifesciences management will attend a Non-Deal Roadshow in Singapore and Hong Kong from August 24 to August 26, 2026. This event is for investor engagement.
Read the summary - Low impact
Zydus Lifesciences Reschedules Investor Conference Participation to August 17, 2026
Zydus Lifesciences Limited's participation in the Motilal Oswal 22nd Annual Global Investor Conference has been rescheduled. The company will now attend the conference on August 17, 2026, instead of the previously announced August 18, 2026.
Read the summary - Medium impact
Zydus Lifesciences Q1 FY27 Net Profit at ₹939.8 Crore, EPS ₹9.35
Zydus Lifesciences reported Q1 FY27 consolidated net profit of ₹939.8 crore, down from ₹1,466.8 crore in the prior year quarter. Total income from operations rose to ₹8,017 crore. EPS was ₹9.35. The results were published on August 12, 2026.
Read the summary - Medium impact
Zydus Lifesciences Appoints Kulin S. Lalbhai as Independent Director, Reappoints Dr. Sharvil P. Patel as MD
Zydus Lifesciences shareholders approved the re-appointment of Dr. Sharvil P. Patel as Managing Director for five years from April 1, 2027. Mr. Kulin S. Lalbhai was appointed as an Independent Director for five years effective May 19, 2026. The decisions were made at the AGM on August 11, 2026.
Read the summary - Medium impact
Zydus Lifesciences Limited: All 9 AGM Resolutions Passed, Including Dividend and Director Re-appointments
Zydus Lifesciences Limited's 31st AGM on August 11, 2026, saw all nine resolutions pass. Key approvals included the FY26 financial statements, a ₹1 dividend, and re-appointments of directors Pankaj R. Patel and Mukesh M. Patel. Dr. Sharvil P. Patel was re-appointed as MD for five years from April 1, 2027.
Read the summary - Low impact
Zydus Lifesciences Posts Q1 FY27 Results; Investor Call Recording Available
Zydus Lifesciences Limited has released the audio recording of its investor call discussing the unaudited financial results for the quarter ended June 30, 2026. The recording is available on the company's website.
Read the summary - Medium impact
Zydus Lifesciences Reports Insider Trading Code of Conduct Violation by Designated Person
Zydus Lifesciences reported a violation of insider trading regulations by Designated Person Ashutosh Patil. He inadvertently traded 171 shares on March 11 and May 22, 2026, valued at ₹3,36,166. The profit of ₹18,797 was transferred to IEPF on August 10, 2026. The Audit Committee noted the violation on August 11, 2026.
Read the summary - Medium impact
Zydus Lifesciences Subsidiary Sentynl Therapeutics Signs Option Agreement for Alvelestat in AATD-LD
Zydus Lifesciences' subsidiary, Sentynl Therapeutics, has an option and license agreement with Mereo BioPharma for alvelestat in AATD-LD. Sentynl can acquire U.S. commercial rights and global manufacturing rights. Mereo may receive up to $40 million in payments and double-digit royalties upon option exercise. Phase 3 development could start in early 2027.
Read the summary - Medium impact
Zydus Lifesciences Q1 FY27 Revenue Up 22% to ₹80,170 Crore; Net Profit Down 36%
Zydus Lifesciences reported Q1 FY27 revenue of ₹80,170 crore, up 22% YoY. Net profit declined 36% to ₹9,398 crore. EBITDA was ₹19,294 crore, down 8%. The company launched its first US biosimilar, NUFYMCO™, and USFDA granted priority review for Saroglitazar Magnesium. An earnings call is scheduled for August 11, 2026.
Read the summary - Medium impact
Zydus Lifesciences Q1 FY27 Revenue Up 22% YoY to ₹8,017 Crore; Net Profit Declines 35.9%
Zydus Lifesciences reported Q1 FY27 revenue of ₹8,017 crore, up 22% YoY. Net profit declined 35.9% to ₹940 crore, with EBITDA margin at 24.1%. Key developments include USFDA priority review for Saroglitazar Magnesium and a JV in Sri Lanka. The company also highlighted its ESG initiatives.
Read the summary - Medium impact
Zydus Lifesciences Launches REVAHALE™, India's First Once-Daily Nebulised LAMA for COPD
Zydus Lifesciences has launched REVAHALE™ (Revefenacin), India's first once-daily nebulised LAMA for COPD maintenance treatment. It offers sustained 24-hour bronchodilation with convenient nebulised delivery, addressing challenges with traditional inhalers. The therapy is compatible with standard jet nebulisers and has shown significant lung function improvements in clinical studies.
Read the summary - Low impact
Zydus Lifesciences to Participate in Motilal Oswal Global Investor Conference on Aug 18, 2026
Zydus Lifesciences Limited will participate in the Motilal Oswal 22nd Annual Global Investor Conference on August 18, 2026. This event is an opportunity for the company to connect with investors.
Read the summary - Medium impact
Zydus Lifesciences Receives USFDA Final Approval for Indocyanine Green Injection
Zydus Lifesciences received USFDA final approval for Indocyanine Green for Injection, a CGT eligible for 180-day exclusivity. The product, a generic equivalent to IC-Green®, had US sales of USD 125.8 million (₹1048 crore). Zydus plans a market launch soon.
Read the summary - Low impact
Zydus Lifesciences: Notice of Loss of Share Certificate Published
Zydus Lifesciences Limited has published a notice regarding the loss of share certificates for multiple shareholders. The company will issue duplicate certificates if no objections are received within 7 days of the August 4, 2026 publication. Public is cautioned against dealing with the lost certificates.
Read the summary - Low impact
Zydus Lifesciences to Participate in Emkay Confluence 2026 on August 13
Zydus Lifesciences Limited will participate in the Emkay Confluence 2026 investor conference on August 13, 2026. This event is an opportunity for the company to engage with investors.
Read the summary - Low impact
Zydus Lifesciences to Participate in Equirus Annual India Conference 2026 on Aug 13
Zydus Lifesciences Limited will participate in the Equirus Annual India Conference 2026 on August 13, 2026. This event is an opportunity for investors to connect with the company.
Read the summary - Medium impact
Zydus Lifesciences Receives USFDA EIR for Injectable Facility with VAI Classification
Zydus Lifesciences received the Establishment Inspection Report (EIR) from the USFDA for its injectable facility in Ahmedabad. The facility was classified as Voluntary Action Indicated (VAI) following a GMP surveillance inspection conducted from April 27 to May 5, 2026.
Read the summary - Medium impact
Zydus Lifesciences Q1 FY27 Results and Earnings Call on Aug 11, 2026
Zydus Lifesciences Limited will declare its Q1 FY27 results on August 11, 2026. An earnings call hosted by Dr. Sharvil Patel is scheduled for the same day at 4:00 PM IST. Presentation and call recordings will be available on the company website.
Read the summary - Medium impact
Zydus Lifesciences Faces ₹10.85 Crore Demand for Stamp Duty and Penalties
Zydus Lifesciences received an order for ₹10.85 crore (₹108.54 million) in stamp duty and penalties related to asset acquisition from Sterling Biotech. The authority valued the assets at ₹154.26 crore (₹1,542.60 million). The company is assessing legal options.
Read the summary - Low impact
Zydus Lifesciences Temporarily Suspends Ahmedabad Operations Due to Heavy Rains
Zydus Lifesciences temporarily suspended operations at its Ahmedabad facilities due to heavy rains and water logging. Operations are now resuming as weather improves. The company has initiated the process to restart activities at the affected sites.
Read the summary - Medium impact
Zydus Life gets nod for Phase III Sickle Cell trial of Desidustat with ICMR
Zydus Lifesciences received approval for a Phase III clinical trial of Desidustat for sickle cell disease patients, in collaboration with ICMR. The trial will enroll 164 patients and evaluate efficacy and safety. Desidustat previously received Orphan Drug Designation from the US FDA for SCD and beta-thalassemia.
Read the summary - Low impact
Zydus Lifesciences Announces 31st AGM on August 11, 2026, with Dividend Payment on August 14
Zydus Lifesciences will hold its 31st AGM on August 11, 2026, via Video Conference. The dividend payment date is set for August 14, 2026. Key dates include July 3 for AGM report entitlement, July 24 for dividend entitlement, and August 4 for e-voting eligibility.
Read the summary - Low impact
Zydus Lifesciences Notifies Shareholders About Unclaimed Shares Transfer to IEPF
Zydus Lifesciences is transferring unclaimed shares and dividends to the IEPF by August 15, 2026. Shareholders who haven't claimed dividends for seven consecutive years are notified. Claims can be made via IEPF-5 form on the MCA website.
Read the summary - Low impact
Zydus Lifesciences Files SEBI Certificate for Q1 FY27 Dematerialization
Zydus Lifesciences Limited submitted its SEBI compliance certificate for the quarter ended June 30, 2026. The RTA confirmed dematerialization processes were completed as per regulations, with share certificates verified, cancelled, and depositories registered as owners.
Read the summary - Medium impact
Zydus Lifesciences Announces 31st AGM on August 11, 2026, Recommends ₹1 Dividend
Zydus Lifesciences will hold its 31st AGM on August 11, 2026, via VC/OAVM. The company recommended a dividend of ₹1 per share for FY26, payable to shareholders of record on July 24, 2026. Members must update KYC and email details by July 22, 2026.
Read the summary - Medium impact
Zydus Lifesciences partners with Apollo Hospitals to launch Shield MCD cancer test
Zydus Lifesciences has partnered with Apollo Hospitals to offer the Shield™ Multi-Cancer Detection (MCD) test in India. This blood test screens for 10 common cancers in individuals aged 45 and older, aiming to improve early detection and reduce cancer mortality. The collaboration with Guardant Health brings innovative screening technology to the Indian market.
Read the summary - Medium impact
Zydus Lifesciences Extends API Business Acquisition Closing Date to Sep 30, 2026
Zydus Lifesciences Limited has extended the closing date for its acquisition of Sterling Biotech Limited's API business to September 30, 2026. This is due to SBL's ongoing completion of certain conditions precedent in the Business Transfer Agreement.
Read the summary - Medium impact
Zydus Lifesciences Forms 50:50 JV with Sunshine Healthcare in Sri Lanka, Investing up to USD 5 Million
Zydus Lifesciences is forming a 50:50 joint venture with Sunshine Healthcare Lanka by subscribing to 50% of Zydus Sunshine Lifesciences. The company will invest up to USD 5 million to establish a pharmaceutical manufacturing facility in Sri Lanka. This facility aims to strengthen local production and reduce import dependence.
Read the summary - Low impact
Zydus Lifesciences Promoters, Directors Accept Shares in Buyback
Zydus Lifesciences Limited announced disclosures from promoters, directors, and KMPs regarding shares accepted in the company's buyback program. The Zydus Family Trust accepted 63,49,542 shares. Various other promoter group members and key personnel also participated in the buyback. Disclosures were made on June 20, 2026.
Read the summary - Medium impact
Zydus Lifesciences Extinguishes 87.3 Lakh Shares Post Buyback
Zydus Lifesciences has extinguished 87.3 lakh equity shares, bought back at ₹1,260 per share for a total of ₹1,100 crore. This action adjusts the company's total issued shares to 99.75 crore.
Read the summary - Low impact
Zydus Lifesciences Publishes Post Buyback Advertisement
Zydus Lifesciences Limited published its post buyback advertisement on June 18, 2026. The buyback involved up to 87.30 lakh shares at ₹1,260 each, with a total size of ₹1,100 crore.
Read the summary - Medium impact
Zydus Lifesciences Completes Merger of Assertio Holdings Inc.
Zydus Lifesciences Limited completed the merger of Zara Merger Sub Inc. into Assertio Holdings Inc., making Assertio a wholly-owned subsidiary. The transaction involved an offer price of USD 23.50 per share, totaling USD 166.33 million (approx. ₹1388 crore). Assertio's product ROLVEDON® had a turnover of USD 68.23 million (approx. ₹570 crore) in CY2025.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio